The possible protective effect of L-carnitine on tilmicosin-induced cardiotoxicity in mice.
The protective effect of L-carnitine was investigated against tilmicosin-induced cardiotoxic effects including blood creatine kinase (CK), CK-MB, total sialic acid as well as the alterations in glutathione and malondialdehyde concentrations in mice. Thirty-two Balb/C mice were divided into four groups including group 1 (control), group 2 (L-carnitine, s.c., 500 mg/kg for 5 days), group 3 (tilmicosin, s.c., single dose of 75 mg/kg) and group 4 (L-carnitine plus tilmicosin). Serum CK, CK-MB and malondialdehyde (MDA) levels were significantly (P < 0.05) higher in group 3 compared with those of other groups. Total sialic acid level in group 3 was found to be significantly (P < 0.05) higher than that in groups 1 and 2, as well. Contrary to these results, glutathione level in group 3 was found to be significantly (P < 0.05) lower than that in groups 1 and 2. In group 4, serum CK, CK-MB, MDA and total sialic acid levels were found to be significantly (P < 0.05) lower than those in group 3. These results suggest that tilmicosin is cardiotoxic in mice as evidenced by higher total sialic acid, CK and CK-MB. In addition, tilmicosin caused the decrease in glutathione and increase in MDA levels. However, administration of L-carnitine could ameliorate these adverse toxic effects of tilmicosin in mice.
Kart
A
A
Department of Pharmacology and Toxicology, College of Vetinary Medicine, University of Kafkas, 36040, Kars, Turkey. asimkart@hotmail.com
Yapar
K
K
Karapehlivan
M
M
Citil
M
M
D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity*; D002331:Carnitine / Q000627:therapeutic use*; D003402:Creatine Kinase / Q000097:blood; D005978:Glutathione / Q000097:blood; D006321:Heart / Q000187:drug effects*; D007279:Injections, Subcutaneous / Q000662:veterinary; D018942:Macrolides / Q000633:toxicity*; D008315:Malondialdehyde / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D019158:N-Acetylneuraminic Acid / Q000097:blood; D011897:Random Allocation; D015645:Tylosin / Q000031:analogs & derivatives* / Q000633:toxicity; D014803:Vitamin B Complex / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D018942:Macrolides; D014803:Vitamin B Complex; D008315:Malondialdehyde; D003402:Creatine Kinase; D005978:Glutathione; D019158:N-Acetylneuraminic Acid; D002331:Carnitine; C052319:tilmicosin; D015645:Tylosin